Mitomycin Substipharm (Mitomycin)

Mitomycin is employed in oncology protocols targeting malignant growths across several organ systems.

• Bladder cancer (intravesical): reduces recurrence after transurethral resection.
• Gastric cancer: contributes to tumor shrinkage when combined with other chemotherapeutics.
• Pancreatic cancer: used in multi‑drug regimens to inhibit cancer cell proliferation.
• Breast cancer: part of combination therapy for advanced or metastatic disease.
• Non‑small cell lung cancer: added to regimens to improve response rates.

• Mitomycin acts as a bioreductive alkylating agent that forms covalent cross‑links between DNA strands. After intracellular activation, it binds to the N2 position of guanine residues, preventing DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing tumor cells.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Myelosuppression: decreased white blood cells, neutrophils, and platelets.
• Fatigue: generalized tiredness often related to anemia.
• Mucositis: inflammation of the mouth and gastrointestinal lining.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Severe bone‑marrow suppression: life‑threatening pancytopenia.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Hemolytic‑uremic syndrome: acute kidney injury with hemolysis.
• Anaphylactic reactions: rapid onset of hypersensitivity.
• Renal toxicity: impaired kidney function, especially with intravesical administration.

Mitomycin requires careful monitoring and specific safety measures before, during, and after administration.

• Blood count monitoring: perform complete blood counts regularly to detect myelosuppression.
• Renal function assessment: evaluate serum creatinine and urine output prior to dosing.
• Pulmonary evaluation: obtain baseline lung function tests in patients with pre‑existing respiratory disease.
• Hypersensitivity screening: avoid use in individuals with known allergy to mitomycin or related compounds.
• Contraception advice: advise both male and female patients of reproductive age to use effective contraception during treatment and for a defined period afterward.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Mitomycin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent myelosuppressive agents (e.g., cyclophosphamide, carboplatin): increase risk of severe bone‑marrow toxicity.
• High‑dose radiation therapy: potentiates tissue damage and mucosal ulceration.
• Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): exacerbate renal impairment.
• Anticoagulants (e.g., warfarin, heparin): heighten bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely)

• NSAIDs: may worsen gastrointestinal irritation and renal effects.
• Diuretics: can affect fluid and electrolyte balance, influencing renal clearance.
• ACE inhibitors or ARBs: monitor blood pressure and kidney function when combined.